HGH Pharmacokinetics: Half-Life, Clearance and the IGF-1 Readout

This page describes the pharmacokinetics of endogenous human growth hormone and of clinically administered somatropin as reported in the literature and regulatory labels. Pharmacokinetics is the study of how a substance is absorbed, distributed, metabolised and eliminated by the body. Every figure here characterises how the hormone behaves inside studied subjects.

Research-use-only: RetaLABS supplies HGH (somatropin) as a laboratory research-use-only compound. The parameters below — half-life, clearance, binding-protein and secretion data — describe endogenous and clinical growth-hormone physiology. They are not a claim about how a research vial behaves, nor any form of dosing, route guidance, or therapeutic recommendation. Endogenous physiology is kept deliberately separate from the research compound throughout.

The companion HGH molecular profile covers the structure, sequence and registry identifiers of the molecule and notes the short intravenous half-life in a single paragraph. This page is the dedicated pharmacokinetic deep-dive: it works through intravenous versus subcutaneous half-life behaviour, the two distinct clearance routes, the GH binding protein, pulsatile diurnal secretion, and why the downstream IGF-1 axis behaves as a long-half-life readout while GH itself is short-lived.

The key fact about growth hormone in the circulation is that it is cleared quickly. When 22 kDa GH is given intravenously to healthy adults (after the endogenous pulse is suppressed so the measurement is clean), the elimination half-life is short and notably diurnally variable: approximately 14 minutes in the morning, rising to about 19 minutes in the evening — the half-life is prolonged in the evening. An independent regulatory cross-check on a somatropin product reports an intravenous terminal half-life of roughly 21 minutes, consistent with the same short range.

Given subcutaneously, the picture changes. The same product whose intravenous terminal half-life is about 0.4 hours shows an apparent half-life of roughly 3 hours after subcutaneous injection on its label. Crucially, this is not because elimination slowed down — the regulatory text states the difference "is due to slow absorption from the subcutaneous injection site." When absorption is slower than elimination, the measured terminal slope reflects the rate of entry into the blood rather than the rate of removal. This is known as absorption-rate-limited (flip-flop) kinetics.

Subcutaneous absorption is rate-limiting and prolongs the apparent half-life relative to intravenous administration. The longer subcutaneous figure describes how fast the hormone arrives, not how fast the body clears it.

Across different somatropin products the subcutaneous apparent half-life clusters in a roughly 2–4 hour band (the ~3 hour value above is one label-verified anchor; other products report figures both lower and higher), and subcutaneous bioavailability relative to intravenous is approximately 80% on that same label. These are descriptions of established absorption physiology drawn from regulatory labels — not instructions, dose figures, or route guidance.

Two distinct mechanisms remove growth hormone from the circulation, and together they explain its short intravenous half-life.

Renal (glomerular) clearance. The kidney handles GH much as it handles other small proteins: the hormone is filtered at the glomerulus, then reabsorbed and degraded in the proximal tubule, with a small amount excreted in the urine. The renal route accounts for a substantial fraction of total metabolic clearance in healthy subjects. The clinical signature of this dependence is directional and well documented — in chronic renal failure the metabolic clearance rate of GH falls roughly by half and the plasma half-life rises, confirming how much of normal GH disposal the kidney performs.

Receptor-mediated clearance. GH is also removed by the very receptor it activates. When GH binds the growth hormone receptor (GHR) at the cell surface, the receptor-ligand complex is internalised by endocytosis. GHR internalisation and degradation are ubiquitin- and proteasome-dependent, with the bound GH ligand following the receptor into lysosomal degradation. This is a clearance and receptor-down-regulation route entirely distinct from glomerular filtration: filtration removes free hormone by size, whereas receptor-mediated uptake removes hormone that is actively engaging a target cell.

The combination of a size-based renal route and a target-based receptor route is what keeps free circulating GH transient — the hormone is removed both by the kidney and by the tissues it signals to.

Not all growth hormone in plasma circulates free. A meaningful fraction is carried bound to a soluble GH binding protein (GHBP), and this binding shapes the apparent pharmacokinetics.

What GHBP is. The high-affinity GHBP is not a separate gene product — it is the soluble extracellular domain of the growth hormone receptor itself. In humans it is generated by proteolytic shedding: a metalloprotease (TACE / ADAM-17) cleaves the GHR ectodomain, releasing the binding portion into the circulation. So the same molecular surface that recognises GH at the cell membrane also exists as a free-floating buffer in plasma.

How much GH is bound. At physiological concentrations a substantial fraction of circulating GH travels in complexed form. Measured directly, about 38.8% is bound; correcting for partial saturation of the binding protein raises the bound fraction to roughly 45% — so, broadly, almost half of plasma GH circulates bound, primarily to the high-affinity receptor-derived binding protein.

By holding roughly half of circulating GH in a bound, slowly exchanging pool, GHBP acts as a buffer and reservoir for free versus bound hormone and prolongs the apparent half-life of circulating GH. Modelling of free and bound GH profiles supports this buffering role; no single fixed "GHBP multiplies the half-life by N" multiplier is asserted.

The practical consequence is that the measured half-life of total GH reflects not only renal and receptor clearance but also the equilibrium between free hormone and the GHBP-bound fraction.

The pharmacokinetics above govern how a given amount of GH disappears. They sit on top of a strongly pulsatile and diurnal pattern of endogenous secretion — a description of normal human endocrine physiology, presented here as background biology and kept separate from any mention of the research compound.

Rather than maintaining a steady level, the anterior pituitary releases GH in multiple discrete secretory bursts across the 24-hour cycle. Secretion follows a circadian rhythm with maximal release in the second half of the night, and the largest single secretory burst is tied to sleep: peak GH levels occur within minutes of the onset of slow-wave (deep) sleep. Between bursts, the short half-life described earlier lets levels fall back toward baseline quickly, which is exactly what produces the sharp peak-and-trough profile.

The interaction matters: because GH is cleared in minutes but secreted in bursts, plasma GH is a spiky, time-of-day-dependent signal. This is also why the intravenous half-life itself reads slightly differently morning versus evening, and why any single "GH level" is only meaningful alongside when in the cycle it was sampled.

If GH is so short-lived, how does the body translate brief nightly bursts into sustained downstream effects? The answer is the IGF-1 axis, which behaves as a long-half-life readout of GH activity.

GH drives hepatic production of insulin-like growth factor 1 (IGF-1). Unlike GH, most circulating IGF-1 does not travel free. It assembles into a ternary complex with IGF-binding protein 3 (IGFBP-3) and the acid-labile subunit (ALS). This IGF-1 / IGFBP-3 / ALS complex is too large to leave the vasculature readily, and it greatly prolongs the half-life of bound IGF to about 16 hours or more, forming a long-lasting circulating reservoir.

Growth hormone is the short-lived signal (minutes); IGF-1 in its ternary complex is the long-lived readout (~16 hours or more). The pulsatile GH input is effectively time-averaged into a far steadier IGF-1 level — which is why IGF-1 is the more stable laboratory index of GH-axis activity than a single GH measurement.

This contrast closes the pharmacokinetic loop: rapid renal and receptor clearance plus GHBP buffering keep GH itself transient and pulsatile, while the IGFBP-3/ALS ternary complex converts that signal into a durable IGF-1 reservoir. For how the molecule itself is built, see the HGH molecular profile.

Sources:

• Holl RW, Schwarz U, Schauwecker P, et al. Diurnal variation in the elimination rate of human growth hormone: the half-life of serum GH is prolonged in the evening. J Clin Endocrinol Metab. 1993;77(1):216–220. PMID 8325945.
• Haffner D, Schaefer F, Girard J, Ritz E, Mehls O. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. J Clin Invest. 1994;93(3):1163–1171. PMID 8132756.
• van Kerkhof P, Govers R, Alves dos Santos CM, Strous GJ. Endocytosis and degradation of the growth hormone receptor are proteasome-dependent. J Biol Chem. 2000;275(3):1575–1580. PMID 10636847.
• Baumann G, Vance ML, Shaw MA, Thorner MO. Plasma transport of human growth hormone in vivo. J Clin Endocrinol Metab. 1990;71(2):470–473. PMID 2380341.
• Schilbach K, Bidlingmaier M. Growth hormone binding protein — physiological and analytical aspects. Best Pract Res Clin Endocrinol Metab. 2015;29(5):671–683. PMID 26522453.
• Veldhuis JD, Johnson ML, Faunt LM, Mercado M, Baumann G. Influence of the high-affinity GH-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. J Clin Invest. 1993;91(2):629–641. PMID 8432866.
• Olarescu NC, Gunawardane K, Hansen TK, Møller N, Jørgensen JOL. Normal physiology of growth hormone in adults. Endotext (NCBI Bookshelf NBK279056).
• Allard JB, Duan C. IGF-binding proteins: why do they exist and why are there so many? Front Endocrinol (Lausanne). 2018;9:117. PMID 29686648.
• Genotropin (somatropin) prescribing information, DailyMed (FDA-sourced): IV terminal t½ 0.4 h, SC t½ 3.0 h, ~80% SC bioavailability.
• Norditropin (somatropin) prescribing information, DailyMed (FDA-sourced): IV terminal t½ ≈21 min cross-check.

Continue across the research cluster: the CJC-1295 with Ipamorelin guide on secretagogue peptides that stimulate endogenous GH release, the peptide reconstitution and storage reference for laboratory handling, and GLP-1 explained for a related signalling-pathway primer.